Di Yi Cai Jing·2025-05-23 14:15Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]